181 related articles for article (PubMed ID: 31954171)
1. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Bashir Q; Qazilbash MH; Andersson BS
Exp Hematol; 2020 Jan; 81():32-41. PubMed ID: 31954171
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
Teo EC; Valdez BC; Ji J; Li Y; Liu Y; Brammer JE; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Lymphoma; 2016 Nov; 57(11):2644-52. PubMed ID: 26980288
[TBL] [Abstract][Full Text] [Related]
3. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
[TBL] [Abstract][Full Text] [Related]
4. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Champlin RE; Andersson BS
Leuk Lymphoma; 2017 Nov; 58(11):2705-2716. PubMed ID: 28394191
[TBL] [Abstract][Full Text] [Related]
5. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.
Valdez BC; Yuan B; Murray D; Ramdial JL; Popat U; Nieto Y; Andersson BS
Oncotarget; 2024 Mar; 15():220-231. PubMed ID: 38484153
[TBL] [Abstract][Full Text] [Related]
6. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Valdez BC; Murray D; Yuan B; Nieto Y; Popat U; Andersson BS
Oncotarget; 2022; 13():319-330. PubMed ID: 35154579
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.
Valdez BC; Yuan B; Murray D; Nieto Y; Popat U; Andersson BS
Leuk Lymphoma; 2022 Jul; 63(7):1634-1644. PubMed ID: 35188042
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
Valdez BC; Wang G; Murray D; Nieto Y; Li Y; Shah J; Turturro F; Wang M; Weber DM; Champlin RE; Qazilbash MH; Andersson BS
Exp Hematol; 2013 Aug; 41(8):719-30. PubMed ID: 23648290
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
11. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
Hunsucker SA; Magarotto V; Kuhn DJ; Kornblau SM; Wang M; Weber DM; Thomas SK; Shah JJ; Voorhees PM; Xie H; Cornfeld M; Nemeth JA; Orlowski RZ
Br J Haematol; 2011 Mar; 152(5):579-92. PubMed ID: 21241278
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
Nieto Y; Yang Z; Valdez BC; Kundu S; Bashir Q; Ramdial J; Srour S; Qazilbash M
Am J Hematol; 2024 Feb; 99(2):245-253. PubMed ID: 38100199
[TBL] [Abstract][Full Text] [Related]
13. CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.
Clarke WR; Amundadottir L; James MA
Int J Cancer; 2019 Mar; 144(6):1367-1378. PubMed ID: 30468251
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
Valdez BC; Tang X; Li Y; Murray D; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2018 Nov; 67():49-59.e1. PubMed ID: 30102945
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
[TBL] [Abstract][Full Text] [Related]
16. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S
Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells.
Tabata M; Tsubaki M; Takeda T; Tateishi K; Maekawa S; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
Clin Exp Med; 2020 Feb; 20(1):63-71. PubMed ID: 31650359
[TBL] [Abstract][Full Text] [Related]
18. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma.
Nakamura A; Suzuki S; Kanasugi J; Ejiri M; Hanamura I; Ueda R; Seto M; Takami A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639102
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
